Skip to content

New Research Shows One‑Size‑Fits‑All Drug Strategy Fails in Heart Failure

By News Analysis India · · 1 min read

Heart failure is a leading cause of hospitalisation worldwide, yet the disease manifests in markedly different ways. In the weakened‑muscle form (HFrEF), the heart cannot generate enough force to move blood, while in the stiff‑muscle form (HFpEF) the ventricle fails to relax, limiting filling between beats. Traditional practice often applies the same drug classes to both groups, especially beta‑blockers that slow heart rate and lower workload. The latest large‑scale study, which examined thousands of patients enrolled in a national clinical trial, revealed that this uniform approach is unsafe for nearly half of those patients. Approximately 80 % of participants were already receiving beta‑blockers, allowing a direct comparison of outcomes. The data showed a sharp increase in adverse events for the HFpEF cohort, challenging the long‑standing belief that beta‑blockers are universally protective.